Theravance Biopharma (TBPH) Short-term Investments (2014 - 2026)

Theravance Biopharma (TBPH) has reported Short-term Investments for 13 consecutive years, with $106.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments rose 426.48% year-over-year to $106.6 million; the TTM figure through Mar 2026 stood at $106.6 million (up 426.48% YoY), while the FY2025 annual figure was $147.6 million, up 191.87% from the prior year.
• Short-term Investments retreated to $106.6 million in Q1 2026 per TBPH's latest filing, from $147.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $154.9 million in Q3 2025 and bottomed at $20.2 million in Q1 2025.
• Historically, Short-term Investments has averaged $66.9 million across 5 years, with a median of $56.9 million in 2025.
• Annual changes were most pronounced in 2022 — Short-term Investments slumped 64.9% — and 2026, when it jumped 426.48%.
• Theravance Biopharma's Short-term Investments stood at $29.3 million in 2022, then jumped by 114.52% to $62.9 million in 2023, then declined by 19.61% to $50.6 million in 2024, then soared by 191.87% to $147.6 million in 2025, then decreased by 27.78% to $106.6 million in 2026.
• Business Quant data shows TBPH's Short-term Investments at $106.6 million in Q1 2026, $147.6 million in Q4 2025, and $154.9 million in Q3 2025.